New hope for hard-to-treat colorectal cancer: targeted drug combo tested in chinese patients
NCT ID NCT06838338
First seen Jan 09, 2026 · Last updated May 15, 2026 · Updated 18 times
Summary
This study tests a new drug (JAB-21822) combined with standard chemotherapy and bevacizumab in people with advanced colorectal cancer that has a specific KRAS G12C mutation. The goal is to see if this combination can shrink tumors or slow the disease in patients who have already tried first-line treatment. About 30 Chinese adults will take part in this early-phase trial.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for COLORECTAL CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Beijing Cancer Hospital
Beijing, China
-
Fudan University Shanghai Cancer Center
Shanghai, China
-
Peking University Cancer Hospital (Inner Mongolia Campus)/Afffliated Cancer Hospital of Inner Mongolia Medical University
Hohhot, China
-
Peking University First Hospital
Beijing, China
Conditions
Explore the condition pages connected to this study.